Vyome Holdings, Inc. (HIND)

Vyome Holdings, Inc. is a biotechnology company developing therapies for immuno-inflammatory and rare diseases. The company became publicly traded through a merger with ReShape Lifesciences, after which the combined company took the Vyome name and focus.

Vyome's work draws on research and development capabilities connected to India along with its U.S. presence, an approach reflected in its strategy of combining scientific and cost advantages across the two countries. Its pipeline includes drug candidates aimed at inflammatory conditions with significant unmet medical need.

Its common stock trades on the Nasdaq under the ticker HIND.